[{"address1": "210 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zip": "94080", "country": "United States", "phone": "650 457 2700", "website": "https://allogene.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.", "fullTimeEmployees": 226, "companyOfficers": [{"maxAge": 1, "name": "Dr. Arie S. Belldegrun F.A.C.S., M.D.", "age": 75, "title": "Co-Founder & Executive Chairman", "yearBorn": 1949, "fiscalYear": 2024, "totalPay": 685292, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. David D. Chang M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, CEO & Director", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 1063565, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joshua A. Kazam", "age": 47, "title": "Co-Founder & Director", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 54000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Zachary J. Roberts M.D., Ph.D.", "age": 46, "title": "Executive VP of Research & Development and Chief Medical Officer", "yearBorn": 1978, "fiscalYear": 2024, "totalPay": 714747, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin M. Beneski", "age": 47, "title": "Senior VP & Chief Technical Officer", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Earl M. Douglas Esq.", "age": 61, "title": "Senior VP, General Counsel, Compliance Officer & Corporate Secretary", "yearBorn": 1963, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Susan R. Lundeen", "age": 58, "title": "Chief People Officer", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Christine  Cassiano", "title": "Executive VP, Chief Corporate Affairs & Brand Strategy Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Annie  Yoshiyama", "age": 40, "title": "SVP & Corporate Controller", "yearBorn": 1984, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 7, "compensationRisk": 10, "shareHolderRightsRisk": 9, "overallRisk": 9, "governanceEpochDate": 1764547200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.42, "open": 1.42, "dayLow": 1.4, "dayHigh": 1.4799, "regularMarketPreviousClose": 1.42, "regularMarketOpen": 1.42, "regularMarketDayLow": 1.4, "regularMarketDayHigh": 1.4799, "payoutRatio": 0.0, "beta": 0.474, "forwardPE": -1.5575981, "volume": 5712234, "regularMarketVolume": 5712234, "averageVolume": 2641182, "averageVolume10days": 2406570, "averageDailyVolume10Day": 2406570, "bid": 1.11, "ask": 1.85, "bidSize": 2, "askSize": 2, "marketCap": 319116800, "fiftyTwoWeekLow": 0.86, "fiftyTwoWeekHigh": 3.78, "allTimeHigh": 55.0, "allTimeLow": 0.86, "priceToSalesTrailing12Months": "Infinity", "fiftyDayAverage": 1.3054, "twoHundredDayAverage": 1.3204, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 152064800, "profitMargins": 0.0, "floatShares": 155030090, "sharesOutstanding": 224730144, "sharesShort": 18663734, "sharesShortPriorMonth": 19094028, "sharesShortPreviousMonthDate": 1761868800, "dateShortInterest": 1764288000, "sharesPercentSharesOut": 0.083100006, "heldPercentInsiders": 0.16699, "heldPercentInstitutions": 0.62995, "shortRatio": 7.8, "shortPercentOfFloat": 0.1, "impliedSharesOutstanding": 224730144, "bookValue": 1.413, "priceToBook": 1.004954, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -212015008, "trailingEps": -0.98, "forwardEps": -0.91166, "enterpriseToEbitda": -0.716, "52WeekChange": -0.27179486, "SandP52WeekChange": 0.1340276, "quoteType": "EQUITY", "currentPrice": 1.42, "targetHighPrice": 14.0, "targetLowPrice": 1.6, "targetMeanPrice": 7.56, "targetMedianPrice": 7.5, "recommendationMean": 1.64286, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 252194000, "totalCashPerShare": 1.122, "ebitda": -212484000, "totalDebt": 85142000, "quickRatio": 7.988, "currentRatio": 8.19, "totalRevenue": 0, "debtToEquity": 27.001, "revenuePerShare": 0.0, "returnOnAssets": -0.27337998, "returnOnEquity": -0.54427, "grossProfits": -166492000, "freeCashflow": -83917752, "operatingCashflow": -158344992, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ALLO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1766190938, "regularMarketTime": 1766178002, "exchange": "NMS", "messageBoardId": "finmb_558022022", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.0, "twoHundredDayAverageChangePercent": 0.07543165, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.6 - Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1539264600000, "postMarketChangePercent": 1.4084578, "postMarketPrice": 1.44, "postMarketChange": 0.0200001, "regularMarketChange": 0.0, "regularMarketDayRange": "1.4 - 1.4799", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 2641182, "fiftyTwoWeekLowChange": 0.55999994, "fiftyTwoWeekLowChangePercent": 0.6511627, "fiftyTwoWeekRange": "0.86 - 3.78", "fiftyTwoWeekHighChange": -2.3600001, "fiftyTwoWeekHighChangePercent": -0.6243387, "fiftyTwoWeekChangePercent": -27.179485, "earningsTimestamp": 1762462800, "earningsTimestampStart": 1762462800, "earningsTimestampEnd": 1762462800, "earningsCallTimestampStart": 1762466400, "earningsCallTimestampEnd": 1762466400, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -0.98, "epsForward": -0.91166, "epsCurrentYear": -0.93669, "priceEpsCurrentYear": -1.5159764, "fiftyDayAverageChange": 0.11459994, "fiftyDayAverageChangePercent": 0.08778914, "twoHundredDayAverageChange": 0.09959996, "shortName": "Allogene Therapeutics, Inc.", "longName": "Allogene Therapeutics, Inc.", "regularMarketPrice": 1.42, "marketState": "CLOSED", "displayName": "Allogene Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-12-20"}]